U.S. Markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.42 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.93 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.01 (-0.01%)
     
  • Gold

    1,753.90
    +2.50 (+0.14%)
     
  • Silver

    22.42
    +0.13 (+0.58%)
     
  • EUR/USD

    1.1738
    -0.0033 (-0.2817%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3741
    -0.0056 (-0.4040%)
     
  • USD/JPY

    109.9080
    +0.1900 (+0.1732%)
     
  • BTC-USD

    47,559.29
    -484.11 (-1.01%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.61%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1%

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Aeglea BioTherapeutics, Inc. AGLE was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $7.59 to $10.50 in the past one-month time frame.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Aeglea BioTherapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Aeglea BioTherapeutics, Inc. Price

Aeglea BioTherapeutics, Inc. Price
Aeglea BioTherapeutics, Inc. Price

Aeglea BioTherapeutics, Inc. price | Aeglea BioTherapeutics, Inc. Quote

Another stock worth considering in the Medical - Biomedical and Genetics industry is Applied Therapeutics, Inc. APLT which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Aeglea BioTherapeutics, Inc. (AGLE) : Free Stock Analysis Report
 
Applied Therapeutics Inc. (APLT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research